The impact of hyperbaric oxygen treatment for cardiovascular implantable electronic devices

被引:0
|
作者
Goto, Kentaro [1 ,3 ]
Miyazaki, Shinsuke [1 ]
Oyaizu, Takuya [2 ]
Negishi, Miho [1 ]
Ikenouchi, Takashi [1 ]
Yamamoto, Tasuku [1 ]
Kawamura, Iwanari [1 ]
Nishimura, Takuro [1 ]
Takamiya, Tomomasa [1 ]
Tao, Susumu [1 ]
Takigawa, Masateru [1 ]
Yagishita, Kazuyoshi [2 ]
Sasano, Tetsuo [1 ]
机构
[1] Tokyo Med & Dent Univ Hosp, Dept Cardiovasc Med, Tokyo, Japan
[2] Tokyo Med & Dent Univ Hosp, Dept Hyperbar, Med Ctr, Tokyo, Japan
[3] Tokyo Med & Dent Univ, Dept Cardiovasc Med, 1-5-45 Yushima,Bunkyo ku, Tokyo 1138510, Japan
关键词
cardiovascular implantable electronic devices; hyperbaric oxygen treatment; CARDIOPULMONARY-RESUSCITATION; THERAPY;
D O I
10.1002/joa3.13070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThe safety of hyperbaric oxygen treatment (HBO2) in patients with cardiovascular implanted electronic devices (CIED) remains unclear.MethodsWe conducted a retrospective analysis of seven CIED patients (median age 79 [73-83] years, five males [71.4%]), including five with pacemakers and two with implantable cardioverter defibrillators (ICD), who underwent HBO2 between June 2013 and April 2023. During the initial session, electrocardiogram monitoring was conducted, and CIED checks were performed before and after the treatment. In addition, the medical records were scrutinized to identify any abnormal CIED operations.ResultsAll seven CIED patients underwent HBO2 within the safety pressure range specified by the CIED manufacturers or general pressure test by the International Organization for Standardization (2.5 [2.5-2.5] atmosphere absolute x 18 [5-20] sessions). When comparing the CIED parameters before and after HBO2, no significant changes were observed in the waveform amplitudes, pacing thresholds, lead impedance of the atrial and ventricular leads, or battery levels. All seven patients, including two with the rate response function activated, exhibited no significant changes in the pacing rate or pacing failure. Two ICD patients did not deactivate the therapy, including the defibrillation; however, they did not experience any arrhythmia or inappropriate ICD therapy during the HBO2.ConclusionCIED patients who underwent HBO2 within the safety pressure range exhibited no significant changes in the parameters immediately after the HBO2 and had no observable abnormal CIED operations during the treatment. The safety of defibrillation by an ICD during HBO2 should be clarified. The patients with CIEDs who underwent HBO2 within the safety pressure range specified by the ICD manufacturers showed no significant changes in the CIED parameters before or immediately after HBO2, and there were no observable abnormalities in the CIED operation during HBO2.image
引用
收藏
页码:958 / 964
页数:7
相关论文
共 50 条
  • [1] Cardiovascular Implantable Electronic Devices in Athletes
    Do, Rose
    Patton, Kristen K.
    CARDIOVASCULAR THERAPEUTICS, 2010, 28 (05) : 327 - 336
  • [2] Infections of Cardiovascular Implantable Electronic Devices
    Baddour, Larry M.
    Cha, Yong-Mei
    Wilson, Walter R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09): : 842 - 849
  • [3] Economic Considerations of Cardiovascular Implantable Electronic Devices for The Treatment of Heart Failure
    Elsner, Christian
    Bettin, Simon
    Tilz, Roland
    Haeckl, Dennis
    CURRENT HEART FAILURE REPORTS, 2024, 21 (03) : 186 - 193
  • [4] Power supplies for cardiovascular implantable electronic devices
    Deng, Jue
    Sun, Xuemei
    Peng, Huisheng
    ECOMAT, 2023, 5 (06)
  • [5] Radiation Safety and Cardiovascular Implantable Electronic Devices
    Bitterman, Danielle S.
    Zei, Paul C.
    Mak, Raymond H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (02): : 243 - 246
  • [6] Update on Cardiovascular Implantable Electronic Devices for Anesthesiologists
    Cronin, Brett
    Essandoh, Michael K.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2018, 32 (04) : 1871 - 1884
  • [7] Candidemia in patients with cardiovascular implantable electronic devices
    Tomofumi Nakamura
    Ryohsuke Narui
    Benjamin Holmes
    Caleb Norton
    Eun-jeong Kim
    Ikutaro Nakajima
    William G. Stevenson
    Matthew H. Greene
    Roy M. John
    Christopher R. Ellis
    George H. Crossley
    Jay A. Montgomery
    Journal of Interventional Cardiac Electrophysiology, 2021, 60 : 69 - 75
  • [8] Candidemia in patients with cardiovascular implantable electronic devices
    Nakamura, Tomofumi
    Narui, Ryohsuke
    Holmes, Benjamin
    Norton, Caleb
    Kim, Eun-jeong
    Nakajima, Ikutaro
    Stevenson, William G.
    Greene, Matthew H.
    John, Roy M.
    Ellis, Christopher R.
    Crossley, George H., III
    Montgomery, Jay A.
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2021, 60 (01) : 69 - 75
  • [9] Bacterial colonization on the cardiovascular implantable electronic devices
    Okada, M.
    Kashiwase, K.
    Hirata, A.
    Higaki, A.
    Ueda, Y.
    EUROPEAN HEART JOURNAL, 2013, 34 : 1031 - 1031
  • [10] Remote monitoring of cardiovascular implantable electronic devices
    Sticherling, Christian
    Kuehne, Michael
    Schaer, Beat
    Altmann, David
    Osswald, Stefan
    SWISS MEDICAL WEEKLY, 2009, 139 (41-42) : 596 - 601